MiMedx Q1 Sales Miss Signals Medicare Cap Pain Accelerating; Guidance Cut.

What happened

MiMedx reported Q1 2026 net sales of $59 million, well below the Q4 2025 run-rate and reflecting the immediate impact of the Medicare skin-substitute payment cap that took effect January 1, 2026. Management revised full-year 2026 net sales and adjusted EBITDA expectations downward, acknowledging that the reimbursement headwind is materializing faster and more severely than previously assumed. The company's efforts to broaden into distributed and surgical products have not yet offset the compression in its core Wound franchise, which faces both pricing and volume pressure. With the stock already down nearly 50% from its 2025 peak, the market has priced in much of the downturn, but the lack of sequential stabilization raises the risk of a bear-case outcome near $3.00. The next 90 days are critical: if Q2 2026 does not show improvement in utilization and cash generation, the thesis that 2026 is merely a 'transition year' will break down.

Implication

This is a high-risk, high-reward turnaround play. If MiMedx can successfully adapt its product mix and restore cash flow, the current valuation (~5.7x EV/EBITDA on depressed earnings) could be attractive. However, investors need clear evidence in Q2 that the portfolio expansion is gaining traction and that the billing/payment friction is easing. Without that, the bear case of a structural decline becomes more probable.

Thesis delta

The previous thesis was to wait for Q1–Q2 evidence of stabilization under the new Medicare payment regime. The Q1 2026 report instead shows deterioration, with a downward revision to full-year guidance, suggesting the headwind is more severe than the base case assumed. The probability of a deeper and more prolonged earnings reset increases, shifting the balance of risk toward the bear scenario ($3.00) unless Q2 shows clear reversal in utilization and cash generation.